DEF: FutureTech II Acquisition Corp. Seeks Shareholder Vote to Extend Business Combination Deadline

FutureTech II Acquisition Corp. is holding a special meeting on August 13, 2026, to vote on extending its deadline to complete a business combination by nine months to May 18, 2027.

Summary

• FutureTech II Acquisition Corp. is convening a special meeting of stockholders on August 13, 2026, to vote on two proposals.
• The primary proposal is to amend the company's charter to extend the deadline for completing a business combination by nine months, from August 18, 2026, to May 18, 2027.
• This extension is sought to allow more time to finalize the previously announced merger with Longevity Biomedical, Inc.
• The second proposal is to grant the chairman the authority to adjourn the meeting if necessary to solicit more votes for the charter amendment.
• Stockholders have the right to redeem their shares for a pro rata portion of the trust account funds, regardless of how they vote on the charter amendment proposal.
• As of June 30, 2026, the trust account held approximately $7.082 million before estimated taxes, equating to about $12.84 per share.
• The company's securities are currently traded on the OTC Markets, which carries risks such as limited liquidity and potential 'penny stock' classification.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the necessity of an extension, the potential for high redemptions, and the risks associated with the company's OTC Market listing, although the extension itself is a standard procedure for SPACs.

Positives

• The proposed extension provides additional time to complete the business combination with Longevity Biomedical, Inc., which management believes is in the best interest of stockholders.
• Stockholders retain the right to redeem their shares for their pro rata portion of the trust account, offering a degree of protection.
• The company's management and board believe the extension is consistent with the charter and IPO prospectus.
• Insider ownership is significant (82.8%), indicating alignment with the company's continued pursuit of a business combination.

Negatives

• The company has not yet completed its initial business combination by the original deadline of August 18, 2026, necessitating this extension vote.
• If the charter amendment is not approved and a business combination is not completed by August 18, 2026, the company will cease operations and liquidate.
• Redemptions by public stockholders could significantly reduce the amount remaining in the trust account, potentially requiring additional funds to complete the business combination.
• The company's securities are traded on the OTC Markets, leading to potential adverse consequences including limited liquidity and 'penny stock' status.

Risks

• Failure to obtain the required 65% stockholder approval for the charter amendment will lead to liquidation.
• Even with the extension, there is no guarantee the business combination will be consummated by May 18, 2027.
• Significant redemptions by public stockholders could deplete the trust account, making the business combination difficult or impossible to complete.
• The company's securities trading on the OTC Markets poses risks related to liquidity, market quotations, and potential 'penny stock' classification, impacting future financing and merger attractiveness.
• Potential challenges in meeting Nasdaq listing requirements for the combined company post-merger.
• The company could be deemed an investment company under the Investment Company Act of 1940, leading to severe restrictions or liquidation.
• Claims by third parties against the Trust Account could reduce the per-share distribution upon liquidation.
• The Sponsor's indemnification obligations may not be fully satisfiable, potentially impacting the Trust Account in case of liquidation.

Future Outlook

The company is seeking to extend its deadline to complete a business combination by nine months to May 18, 2027, to allow more time to finalize the merger with Longevity Biomedical, Inc. Management believes it can close the business combination before December 31, 2026, but is seeking the extension out of an abundance of caution. If the extension is not approved and a business combination is not completed by August 18, 2026, the company will liquidate.

Management Comments

• The Board believes that in order to be able to complete the Business Combination, we will need to obtain the Extension.
• Without the Extension, the Board believes that there is significant risk that we might not, despite our best efforts, be able to complete the Business Combination on or before the Termination Date.
• The Board believes that it is in the best interests of the stockholders to continue FutureTechs existence until the Extended Date to complete and close the Business Combination.
• The Board recommends that FutureTechs stockholders vote FOR the Charter Amendment Proposal.

Industry Context

StockSavvy.ai notes that SPACs frequently require extensions to complete their business combinations, especially in challenging market conditions or when complex deals are involved. The need for an extension, coupled with the potential for significant redemptions, highlights the ongoing pressures faced by SPACs in the current economic environment.

Comparison to Industry Standards

• Many SPACs, particularly those formed in 2021 and 2022, have faced difficulties in finding and closing business combinations within their initial timeframes, leading to frequent requests for extensions.
• The redemption rates for SPACs vary significantly based on market sentiment and the perceived attractiveness of the target company. High redemption rates can deplete the trust account, impacting the viability of the transaction.
• The requirement for a supermajority vote (65%) to approve charter amendments for extensions is a common feature in SPAC structures, designed to protect public stockholders but also posing a hurdle for management.
• The current market for de-SPAC transactions is challenging, with many companies experiencing post-merger stock price underperformance, making the successful completion and integration of a business combination critical.

Related Party Transactions

• The Sponsor, FutureTech Partners II LLC, has provided working capital loans and convertible loans to the company, totaling $3,579,891 outstanding as of June 30, 2026.
• The Sponsor has agreed to deposit funds into the Trust Account for monthly extensions, in exchange for non-interest bearing promissory notes.
• Founder shares held by the Sponsor, officers, and directors are subject to lock-up periods.
• The Sponsor and its affiliates are expected to vote in favor of the Charter Amendment Proposal.

Stakeholder Impact

• Public stockholders have the right to redeem their shares for cash if they do not wish to proceed with the extension or the potential business combination.
• If the Charter Amendment is not approved and the company liquidates, public stockholders will receive their pro rata share of the Trust Account.
• Warrant holders will see their warrants expire worthless if the company liquidates.
• The Sponsor and initial stockholders may lose their entire investment if a business combination is not completed, but they have waived liquidation rights on their founder shares.

Next Steps

• Stockholders to vote on the Charter Amendment Proposal and Adjournment Proposal at the Special Meeting on August 13, 2026.
• If the Charter Amendment Proposal is approved, FutureTech will file an amendment to its charter to extend the business combination deadline.
• FutureTech will continue to work towards completing the business combination with Longevity Biomedical, Inc. by the Extended Date (May 18, 2027).
• If the Charter Amendment Proposal is not approved and a business combination is not completed by August 18, 2026, the company will cease operations and liquidate.

Key Dates

Recommendation

The filing is primarily procedural, seeking an extension for a SPAC to complete its business combination. While the extension itself is common, the underlying business combination with Longevity Biomedical, Inc. is not detailed enough here to warrant a strong buy or sell. The risks associated with OTC trading and potential redemptions suggest a 'hold' recommendation pending further clarity on the business combination and its market viability.

Keywords

FutureTech II Acquisition Corp., Special Meeting, Charter Amendment, Business Combination, Extension, Longevity Biomedical, SPAC, Redemption